Advisor Partners LLC raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 5.8% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 34,579 shares of the biopharmaceutical company’s stock after acquiring an additional 1,891 shares during the period. Advisor Partners LLC’s holdings in Bristol-Myers Squibb were worth $1,927,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Welch Investments LLC lifted its stake in shares of Bristol-Myers Squibb by 3.9% in the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 79 shares during the period. Blue Chip Partners Inc. lifted its stake in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares during the period. Proficio Capital Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 504 shares during the period. American National Bank lifted its stake in shares of Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 225 shares during the period. Finally, Heritage Trust Co acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $123,000. Institutional investors own 68.84% of the company’s stock.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Theodore R. Samuels II acquired 6,000 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by corporate insiders.
Several brokerages recently commented on BMY. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Jefferies Group LLC cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective for the company. in a research note on Monday. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective for the company. in a research note on Thursday, September 28th. Finally, Barclays PLC raised their price objective on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $63.21.
TRADEMARK VIOLATION WARNING: This news story was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://weekherald.com/2017/10/17/bristol-myers-squibb-company-bmy-stake-increased-by-advisor-partners-llc.html.
Bristol-Myers Squibb Company (BMY) opened at 63.65 on Tuesday. The firm has a market cap of $104.38 billion, a PE ratio of 23.25 and a beta of 1.19. The firm’s 50-day moving average is $62.78 and its 200-day moving average is $56.98. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the prior year, the company earned $0.69 EPS. Bristol-Myers Squibb’s revenue was up 5.6% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 56.73%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.